Amylin (AMLN) Announces BYETTA Approved As Stand-Alone Medication

November 2, 2009 7:23 AM EST

Over the weekend, Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that the FDA has approved an expanded indication for BYETTA injection.

BYETTA is now approved for use as a stand-alone medication along with diet and exercise to improve glycemic control in adults with type 2 diabetes. Previously, it was approved for use only in patients who were also taking other common diabetes medications and had not achieved adequate glycemic control.


Related Categories

FDA

Stocks Mentioned

AMLN 12.47

+0.03 +0.24%
Volume: 1,157,567
Track AMLN

LLY 36.80

+0.21 +0.57%
Volume: 5,129,145
Track LLY


Add Your Comment